Portal de investigação
Everolimus resistance in clear cell renal cell carcinoma: miRNA-101 and HIF-2a as molecular triggers?
Autores da FMUP
Participantes de fora da FMUP
- Nogueira, I
- Dias, F
- Morais, M
- Teixeira, AL
Abstract
Aim: The majority of clear cell renal cell carcinoma patients develop resistance to mTOR inhibitors. Materials & methods: As an in vitro model four cell lines were used: HKC-8, 786- O, RCC-FG-2 and an everolimus-resistant cell line (786-OR) established during this study. The quantification of miRNA-101 and HIF-2 alpha mRNA levels was assessed by real-time PCR. Results: We observed a significant decrease of miRNA-101 intracellular levels in 786-OR. However, this miRNA presented higher extracellular levels. Additionally, we found a significant increase of HIF-2 alpha in 786-OR. Conclusion: The circulating levels of miRNA-101 may be a potential biomarker of anti-mTOR therapy response and resistance prediction. Moreover, the resistance to mTOR inhibitors seems to be related with the overexpression of HIF-2 alpha.
Dados da publicação
- ISSN/ISSNe:
- 1744-8301, 1479-6694
- Tipo:
- Article
- Páginas:
- 2361-2370
Future Oncology Future Medicine Ltd.
Citações Recebidas na Web of Science: 10
Documentos
- Não há documentos
Filiações
Keywords
- clear cell renal cell carcinoma; everolimus-resistance; HIF-2 alpha; miRNA-101; mTOR inhibitors
Financiamento
Proyectos asociados
Previsão das readmissões dos doentes à Urgência Pediátrica: aplicação das técnicas de aprendizagem supervisionadas.
Investigador Principal: Rui Manuel de Medeiros Melo Silva
Estudo Observacional Académico (UrgPediatr) . 2019
Citar a publicação
Nogueira I,Dias F,Morais M,Teixeira AL,Medeiros R. Everolimus resistance in clear cell renal cell carcinoma: miRNA-101 and HIF-2a as molecular triggers?. Future Oncol. 2019. 15. (20):p. 2361-2370. IF:2,660. (3).
